Examples of using Combination with melphalan in English and their translations into German
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Frequency of adverse reactions with thalidomide in combination with melphalan and prednisone.
Lenalidomide in combination with melphalan and prednisone followed by maintenance monotherapy in patients who are not eligible for transplant.
Table 2: Recommended posology for Bortezomib Accord in combination with melphalan and prednisone.
When used in combination with melphalan and prednisone, Velcade is given twice a week on weeks 1, 2, 4 and 5 of a six-week treatment cycle.
Dose modification andre-initiation of therapy when VELCADE is administered in combination with melphalan and prednisone.
Recommended posology for VELCADE in combination with melphalan and prednisone for patients with previously untreated multiple myeloma Twice weekly VELCADE cycles 1-4.
Table 3:Posology modifications during subsequent cycles of Bortezomib Accord therapy in combination with melphalan and prednisone.
Venous thromboembolism was seen to a lesser extent with lenalidomide in combination with melphalan and prednisone in newly diagnosed multiple myeloma and with monotherapy in myelodysplastic syndromes.
No dose adjustment is proposed for patients older than 75 years who are treated with lenalidomide in combination with melphalan and prednisone.
Thalidomide Celgene is used to treatmultiple myeloma(a cancer of the bone marrow) in combination with melphalan and prednisone(anticancer medicines) in patients who have not been treated for multiple myeloma before.
Overall, the safety profile of patients treated with VELCADE in monotherapy wassimilar to that observed in patients treated with VELCADE in combination with melphalan and prednisone.
Thalidomide Celgene is taken in treatment cycles,each cycle lasting 6 weeks, in combination with melphalan and prednisone which are taken on days 1 to 4 of each 6 week cycle.
VELCADE in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.
Newly diagnosed multiple myeloma in patients treated with lenalidomide in combination with melphalan and prednisone.
The clinically important adverse reactions associated with the use of thalidomide in combination with melphalan and prednisone or dexamethasone include: deep vein thrombosis and pulmonary embolism, peripheral neuropathy, severe skin reactions including Stevens Johnson Syndrome and toxic epidermal necrolysis, syncope, bradycardia, and dizziness see sections 4.2, 4.4 and 4.5.
The risk of occurrence of hematologicSPM must be taken into account before initiating treatment with Revlimid either in combination with melphalan or immediately following high-dose melphalan and ASCT.
This increase was not observed in clinical trials of newly diagnosed multiple myeloma in patients taking lenalidomide in combination with low dose dexamethasone compared to thalidomide in combination with melphalan and prednisone.
Venous thromboembolism was seen to a lesser extent with lenalidomide in combination with melphalan and prednisone in newly diagnosed multiple myeloma.
Frequencies given are based on the observations during a pivotal comparativeclinical study investigating the effect of thalidomide in combination with melphalan and prednisone in previously untreated multiple myeloma patients.
A 2.12-fold increase in incidence rate of solid tumour SPM has beenobserved in patients receiving lenalidomide(9 cycles) in combination with melphalan and prednisone(1.57 per 100 person-years) compared with melphalan in combination with prednisone 0.74 per 100 person-years.
Cases of AML have been observed in clinical trials of newly diagnosed multiplemyeloma in patients taking lenalidomide treatment in combination with melphalan or immediately following high dose melphalan and ASCT see section 4.4.
A prospective Phase III, international, randomised(1:1), open-label clinical study(MMY-3002 VISTA) of 682 patients was conducted todetermine whether VELCADE(1.3 mg/m2 injected intravenously) in combination with melphalan(9 mg/m2) and prednisone(60 mg/m2) resulted in improvement in time to progression(TTP) when compared to melphalan(9 mg/m2) and prednisone(60 mg/m2) in patients with previously untreated multiple myeloma.
In clinical trials of newly diagnosed multiple myeloma patients not eligible for transplant, a 4.9-fold increase in incidence rate of hematologic SPM(cases of AML, MDS)has been observed in patients receiving lenalidomide in combination with melphalan and prednisone until progression(1.75 per 100 person-years) compared with melphalan in combination with prednisone 0.36 per 100 person-years.
Bortezomib Hospira therapy should be withheld when the platelet count is< 25,000/μl or,in the case of combination with melphalan and prednisone, when the platelet count is≤ 30,000/μl see section 4.2.
Clinical efficacy in previously untreated multiple myeloma A prospective Phase III, international, randomised(1:1), open-label clinical study(VISTA) of 682 patients wasconducted to determine whether VELCADE(1.3 mg/ m2) in combination with melphalan(9 mg/ m2) and prednisone(60 mg/ m2) resulted in improvement in time to progression(TTP) when compared to melphalan(9 mg/ m2) and prednisone(60 mg/ m2) in patients with previously untreated multiple myeloma.